Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
CC transcript
Credit agrmnt [a]
Acq. announced
Appointed director
IMPAX LABORATORIES INC (IPXL) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/14/2019 SC 13G/A MAVERICK CAPITAL LTD reports a 0% stake in IMPAX LABORATORIES, INC.
02/12/2019 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
06/07/2018 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
05/10/2018 10-Q Quarterly Report for the period ended March 31, 2018
05/07/2018 SC TO-I Form SC TO-I - Tender offer statement by Issuer:
05/07/2018 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : May 7, 2018 IMPAX LABORATORIES, LLC Delaware 001-34263 65-0403311 30831 Huntwood Avenue, Hayward, CA 94544 240-6000 Registrant's telephone number, including area code Impax Laboratories, Inc. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-...",
"Form of Amended and Restated Certificate of Incorporation of Impax Laboratories, Inc",
"Form of Amended and Restated Bylaws of Impax Laboratories, Inc",
"Limited Liability Company Agreement of Impax Laboratories, LLC",
"Second Supplemental Indenture",
"Term Loan Credit Agreement, by and among Amneal Pharmaceuticals LLC, as the borrower, JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the lenders and other parties party thereto",
"Revolving Credit Agreement, by and among Amneal Pharmaceuticals LLC, as the borrower, the other loan parties from time to time party thereto, JPMorgan Chase Bank, N.A., as administrative agent and collateral agent and the lenders and other parties party thereto",
"Term Loan Guarantee and Collateral Agreement, by and among the loan parties from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent",
"Revolving Loan Guarantee and Collateral Agreement, by and among the loan parties from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent",
"Termination Agreement, , between Impax Laboratories, LLC (f/k/a Impax Laboratories, Inc.) and Royal Bank of Canada"
05/04/2018 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
04/30/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "AMNEAL AND IMPAX RECEIVE FTC CLEARANCE FOR BUSINESS COMBINATION"
04/13/2018 10-K/A Annual Report for the period ended December 31, 2017 [amend]
04/10/2018 SC 13G/A VANGUARD GROUP INC reports a 10.1% stake in Impax Laboratories Inc
04/05/2018 CT ORDER Form CT ORDER - Confidential treatment order:
03/27/2018 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Impax Shareholders Approve Proposed Business Combination with Amneal"
03/19/2018 425 Form 425 - Prospectuses and communications, business combinations:
03/19/2018 8-K Other Events
03/15/2018 425 Form 425 - Prospectuses and communications, business combinations:
03/07/2018 8-K Regulation FD Disclosure
03/02/2018 425 Form 425 - Prospectuses and communications, business combinations:
03/01/2018 425 Form 425 - Prospectuses and communications, business combinations:
03/01/2018 10-K Annual Report for the period ended December 31, 2017
03/01/2018 425 Form 425 - Prospectuses and communications, business combinations:
03/01/2018 8-K Investor presentation, Quarterly results
Docs: "Impax Reports Fourth Quarter and Full Year 2017 Results ‒ Q4 2017 Total Revenues of $183 Million; GAAP Net Loss Per Share of $4.18; Non-GAAP Adjusted Income Per Share of $0.11 ‒ ‒ Full Year 2017 Total Revenues of $776 Million; GAAP Net Loss Per Share of $6.53; Non-GAAP Adjusted Income Per Share of $0.63 ‒ ‒ Completes Operational and Cost Improvement Plans ‒ ‒ Combination with Amneal Pharmaceuticals Expected to Close in the Second Quarter of 2018 &#8210",
"Presentation"
02/14/2018 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/12/2018 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
02/12/2018 SC 13G MAVERICK CAPITAL LTD reports a 9.9% stake in IMPAX LABORATORIES, INC.
02/09/2018 SC 13G/A VANGUARD GROUP INC reports a 9.5% stake in Impax Laboratories Inc
02/08/2018 SC 13G WELLINGTON MANAGEMENT GROUP LLP reports a 5.6% stake in Impax Laboratories, Inc.
02/06/2018 SC 13G/A Invesco Ltd. reports a 2.6% stake in Impax Laboratories Inc
02/06/2018 425 Form 425 - Prospectuses and communications, business combinations:
02/01/2018 425 Form 425 - Prospectuses and communications, business combinations:
01/25/2018 425 Form 425 - Prospectuses and communications, business combinations:
01/24/2018 425 Form 425 - Prospectuses and communications, business combinations:
01/24/2018 8-K Other Events
01/19/2018 SC 13G/A BlackRock Inc. reports a 13.3% stake in IMPAX LABORATORIES INC
01/09/2018 425 Form 425 - Prospectuses and communications, business combinations:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy